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Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81A46freely along a papered walkway. Gait scoring and quantiﬁcation was
performed using 4 distinct pawprint pairs per animal, collected daily for
4 days following each reactivation.
Results: GZ389988 was identiﬁed as a potent inhibitor of TrkA (similar
IC50 values observed for TrkA, TrkB, TrkC and cFMS/CSF1R), with a high
level of selectivity against a wide panel of other kinases. In addition,
GZ389988 has very low aqueous solubility, thus facilitating its for-
mulation for local administration. No cytotoxicity was observed in cell-
based assays using criteria of LD50/IC50 ratio >100. In vivo bio-
compatibility studies with GZ389988 showed neither a treatment effect
on body weight or clinical appearance, nor any signiﬁcant histopatho-
logic changes in joint tissues.
In the rat MIA model, a single ipsilateral dose of GZ389988 provided a
signiﬁcant reduction in local joint pain (weight-bearing imbalance) for
4 weeks. Treatment of the contralateral joint with GZ389988 had no
effect on ipsilateral joint pain (Fig. 1), illustrating the absence of a
substantial systemic effect following IA administration. GZ389988 was
also efﬁcacious in the PGPS arthritis model, demonstrating a signiﬁcant
improvement of gait analysis scores following painful disease reac-
tivation ﬂares (Fig. 2).
Conclusions: Elevated levels of NGF are associated with tissue injury,
and have been observed in a number of painful conditions including OA.
In addition, TrkA is expressed by OA synovial ﬁbroblasts and is upre-
gulated in response to NGF. In OA pain trials, NGF-blocking Abs have
demonstrated signiﬁcant efﬁcacy with high patient responder rates,
however such studies have been subject to clinical hold by the FDA due
to the occurrence of joint-related adverse events. We have targeted the
NGF pain signaling pathway using a locally-effective inhibitor of TrkA.
In addition to the efﬁcacy data presented here, pharmacokinetic studies
and safety pharmacology and preclinical toxicology data support the
development of GZ389988 as a novel therapeutic approach for the
treatment of OA and joint pain.
Figure 1. Efﬁcacy of GZ389988 in rat MIA model of joint pain. Disease was
initiated by a single IA injection of MIA into the knee joint (ipsilateral).
One week later, a single dose of GZ389988 was administered by IA
injection into the ipsilateral or contralateral knee. Differences in hind limb
weight-bearing distribution were measured immediately prior to injec-
tion of MIA (baseline; BL) and GZ389988 (Time 0), and weekly thereafter
for 4 weeks. Data are presented as mean þ SEM.
Figure 2. Efﬁcacy of GZ389988 in rat PGPS model of joint pain. Disease
was inititated by a single IA injection of PGPS into the knee joint (ipsi-
lateral) three weeks prior to the ﬁrst reactivation. A single dose of
GZ389988 was administered by IA injection into the knee one week prior
to the ﬁrst reactivation. Disease reactivation (painful ﬂare) was induccd on
study days 0 and 14 by IV administration of PGPS. Gait analysis was
performed based on pawprint areas, and scored as follows: 1¼ mild
limping/pain; 2¼moderate limping/pain; 3¼marked limping/pain;
4¼severe hopping/pain. Data are presented as mean þ SEM.37
EFFICACY OF HYDROXYCHLOROQUINE IN PRIMARY HAND
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Purpose: Current pharmacological treatment of hand osteoarthritis
(hand OA) is limited. Treatment options consist of the use of analge-
sics, such as paracetamol or (topical) non-steroidal anti-inﬂammatory
drugs (NSAIDs) and corticosteroids. Although these medications can
provide some relief for patients with mild joint pain, their effect is
temporary and mostly insufﬁcient for patients with more severe
symptoms. Furthermore, chronic use of NSAIDs and corticosteroids is
not recommended because of its potential (serious) side effects.
Hydroxychloroquine (HCQ) has been used successfully in the treat-
ment of mild rheumatoid arthritis and other auto-immune diseases
for many years. The suppression of inﬂammation by inhibition of
cytokines is believed to be part of the mechanism of action. Pain in
hand OA is associated with inﬂammation as well; therefore HCQ
might also be beneﬁcial in hand OA. So far there has only been a few
poor quality retrospective trials that have proven some beneﬁcial
effect of HCQ in hand OA. This is the ﬁrst randomized, double-blind,
placebo-controlled trial to study the symptom modifying effect of HCQ
in hand OA.
Methods: Patients were recruited from outpatient rheumatology clinics
from 6 different hospitals, including one university medical center, in
and around Rotterdam (the Netherlands). Patients,  40 years of age,
with primary hand OA according to the ACR classiﬁcation criteria were
included. Patients with  1 hand joint with a Kellgren and Lawrence
grade 4 were excluded. Hand pain symptoms, independent of level of
severity, had to be present for at least one year. Patients were randomly
assigned to receive either HCQ 400 mg once a day or placebo during a
treatment period of 24 weeks. Paracetamol was used as rescue medi-
cation and patients were allowed to continue all comedication except
NSAIDs during the study. If patients were using NSAIDs, inclusion was
allowed after a wash out period of 1 week. The primary outcome was
decrease of hand pain in the previous 24 hours on a 100 mm visual
analogue scale (VAS) at the end of the study. Secondary outcomes
included change in total score of the Australian Canadian Hand Osteo-
arthritis Index (AUSCAN) and the Arthritis Impact Measurement Scale 2
SF (AIMS2-SF) at the end of the study. Friedman test is used for the
analysis of non-normally distributed data (VAS pain). Repeated meas-
ures ANOVA was used for the normally distributed data (AUSCAN en
AIMS2-SF scores). Multiple imputation (50 imputations) was used to
impute all missing data. Intention to treat analyses were performed in
SPSS v20.0.
Results: Two hundred and two patients were included from July 2010
till December 2013. Six patients who were lost to follow up at an early
stage of the study (i.e. no data at any time point), were excluded from
the analysis. An intention to treat analysis was performed on the
remaining 196 patients (HCQ n ¼ 98, placebo n ¼ 98). No differences
were seen in baseline characteristics between the groups: 86% of the
patients were female, the mean age was 57 years. Twenty-one patients
in the HCQ group and 8 patients in the placebo group discontinued
study medication before 24 weeks. The most reported reasons were
adverse drug events and lack of efﬁcacy. At baseline the median (25th
-75th percentile) VAS pain was 45 mm (26-60) in the HCQ group and
50 mm (25-63) in the placebo group. The mean (SD) total AUSCAN
score was 5.2 (1.9) in the HCQ group and 5.0 (1.9) in the placebo group
(0 - 10 scale). The mean (SD) total AIMS2-SF score was 3.7 (1.2) in the
HCQ group and 3.9 (1.2) group (0 - 10 scale). After 24 weeks the
median (25th -75th percentile) VAS pain was 36 mm (16-58) and 48
mm (23-62) in the HCQ and placebo groups respectively. The
decreases in pain were not statistically signiﬁcant within the groups.
Also, no statistically signiﬁcant difference was seen between the
intervention and placebo group at any time point (t ¼ 0, 6, 12, 24
weeks) for VAS pain scores, AUSCAN total and subscales or AIMS-SF2
outcomes.
Conclusions: This study shows that 24 weeks of treatment with HCQ in
symptomatic hand OA did not reduce pain when compared to placebo.
Also, no effect was observed in change of AUSCAN total and subscales
scores or AIMS2-SF scores between both treatment groups. These
results suggest that HCQ should not be prescribed in patients with
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A47primary hand OA with mild to moderate pain symptoms. Further
investigation is required to determine the efﬁcacy of HCQ in other hand
OA phenotypes.
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THE EFFECT OF WALKING EXERCISE REGIMENS ON JOINT
BIOMECHANICS AND SERUM BIOMARKER PROFILE IN PATIENTS
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Purpose: Although walking exercise is commonly prescribed to
patients with knee osteoarthritis (OA), there is limited evidence
regarding the safe mode and volume of walking exercise beyond which
a patient may be potentiating further joint damage leading to reduced
clinical beneﬁts. The present study is the ﬁrst that aims to determine
the speciﬁc features of a walking exercise program beyond which
accelerated rates of joint damage are expected using both bio-
mechanical and biochemical outcome measures. Objective 1: Deter-
mine the inﬂuence of increasing walking volume as a single continuous
session versus multiple intermittent shorter sessions on knee joint
biomechanics as assessed by the change in the knee contact force (KCF)
proﬁle. Objective 2: Investigate the effect of continuous versus inter-
mittent walking regimen on serum concentration of a biomarker that
has been associated with cartilage turnover (cartilage oligomatrix
protein, COMP).
Methods: Twenty-eight subjects aged >50 with unilateral sympto-
matic knee OA who met the American College of Rheumatology
clinical criteria and a Kellgren-Lawrence radiographic OA grading of
>2 were recruited. All subjects completed two walking exercise ses-
sions separated by at least 72 hours: 1) a single session of 45 minutes
of continuous walking, and 2) three separate 15-minute bouts of
walking with a 1-hour rest period between each bout, for a total of 45
minutes of walking exercise. For both walking sessions, biomechanical
data consisting of passive marker trajectories and ground reaction
force data along with 5-ml blood samples were collected at baseline
and after every 15 minutes of cumulative walking exercise. Passive
marker trajectories and ground reaction force data were used to create
subject speciﬁc, muscle driven, gait simulations using Opensim to
estimate the ﬁrst and second peaks in the KCF while walking on a
treadmill. Additionally, serum concentration of COMP was quantiﬁed
using ELISA. To determine whether KCFs or Serum COMP concen-
trations varied between continuous and intermittent walking con-
ditions, a 2x4 (condition x walking time) factorial analysis of variance
(ANOVA) with repeated measures was performed for each variable of
interest.
Results: A signiﬁcant walking time effect was observed for the ﬁrst peak
in KCF (F3,81¼ 5.52, P ¼ 0.002) but there was no condition effect or a
condition x walking time interaction. When averaged across the two
walking conditions, post-hoc analysis revealed a signiﬁcant increase in
the ﬁrst peak of KCF equivalent to 25% of body weight after 30 minutes
(P¼0.004) and 45 minutes of cumulative walking (P¼0.009). No con-
dition effect, walking time effect, or condition x walking time inter-
action was observed for the second peak in KCF. A signiﬁcant condition
x walking time interaction (F3,81¼3.50, P¼ 0.02) was also observed for
the changes in COMP concentration, but there were no signiﬁcant
condition effect or walking time effect. Continuous walking was asso-
ciated with a signiﬁcant cumulative increase in COMP concentration
from baseline to 45 minutes (23% increase, P < 0.05), whereas, COMP
concentrations dropped to baseline levels after 30 minutes of inter-
mittent walking with rest breaks.
Conclusions: Cumulative increases in walking exercise volume of
greater than 30 minutes (irrespective of walking regimen) were asso-
ciated with an increase in the ﬁrst peak in KCF equivalent to 25% of body
weight, suggesting a signiﬁcant increase in articular cartilage loading
proﬁles that may be undesirable. The continuous walking regimen
appeared to potentiate an increase in serum COMP concentration at 45
minutes, while an intermittent walking regimen that involved rest
breaks did not. Together our preliminary ﬁndings suggest that pre-
scription of walking exercise of greater than 30 minutes may lead to
undesirable joint loading conditions, while addition of rest breaks may
attenuate the potential negative effects of longer bouts of walking
exercise on cartilage health.39
ADDRESSING CONTROVERSIES AROUND INTRA-ARTICULAR
INJECTIONS WITH HYALURONIC ACID IN THE TREATMENT OF
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Purpose: Intra-Articular injections (IA) with hyaluronic acid (HA) are
used for treating symptomatic osteoarthritis (OA), despite divergent
opinions concerning its effectiveness. The aim of this study was to
explore and identify factors from randomized trials (RCTs), which
explain controversies around the potential efﬁcacy of IA HA compared
to IA sham, IA control, or non-intervention control therapies in patients
with symptomatic OA of the knee, hip and other joints.
Methods: A systematic review and stratiﬁed meta-analysis of available
RCTs was conducted. Methods of the analysis and inclusion criteria
were speciﬁed in advance and registered in the International Pro-
spective Register of Systematic Reviews, PROSPERO registration no.
CRD42014007284. MEDLINE, EMBASE, Cochrane Central Register of
Controlled trials (CENTRAL), Web of science and other resources were
searched for trials in any language. The outcome “pain” was assessed
according to a pre-speciﬁed hierarchy of potentially available outcomes.
Reviewers used duplicate abstractions and independently assessed risk
of bias using the risk of bias tool recommended by Cochrane Collabo-
ration. Hedges’s standardized mean difference (SMD [95%CI]) served as
effect size. REstricted Maximum Likelihood (REML) mixed-effects
models were used to combine study results calculating I-squared and
Tau-squared estimates using STATA. To empirically quantify reasons for
the apparent heterogeneity across studies, a number of stratiﬁed
analyses of the primary outcome were performed according to the trial
characteristics.
Results: Ninety-nine trials, including 115 comparisons (14,804
patients), met the inclusion criteria: Of these, 85 comparisons (11,216
patients) had adequate data available for enabling inclusion in the
meta-analysis. Compared with control, HA reduced pain with an effect
size of -0.39 [-0.47 to -0.41; P<0.001]. There was a high level of
inconsistency (I2¼73%). Adjusting for selective outcome reporting in 30
of the comparisons by imputing data from “null ﬁndings” for the studies
that did not report on pain reduced the combined estimate to -0.30
[-0.37 to -0.23; P<0.001]. Three important variables explaining the high
heterogeneity were overall risk of bias, blinding of personnel and trial
size. Overall risk of bias reduced the heterogeneity (according to Tau-
squared) by 26 %, showing an effect size for low risk of bias trials of
-0.00 [-0.13 to 0.12] compared to -0.35 [-0.43 to -0.27] and -0.81 [-1.19
to -0.44] for high and unclear risk of bias, respectively. Furthermore,
blinding of personnel and trial size reduced the heterogeneity by 26%
and 25% respectively (interaction P<0.001).
Conclusions: Based on available trials, IA HA showed statistically sig-
niﬁcant clinical effect. Small-study bias and the risk of selective out-
come reporting, suggest a lower effect size corresponding to a small,
although statistically signiﬁcant, effect. Stratiﬁed analyses showed
three important variables explaining heterogeneity; Overall Risk of Bias,
blinding of personnel and trial size. Trials with low risk of bias did not
seem to be associated with effect.
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DOES PATELLO-FEMORAL BRACE THERAPY REDUCE SYNOVITIS
ASSESSED BY DYNAMIC CONTRAST ENHANCED MRI?
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Purpose: Osteoarthritis (OA) is associated with inﬂammatory changes
within an affected joint including synovitis. We previously demon-
strated that a patellar brace both reduced pain and decreased MRI
bone marrow lesions in patellofemoral joint (PFJ) OA. While static
synovial volume was not affected by this brace, RA studies and our
ﬁndings in a steroid trial (OARSI, 2014) suggest that changes in the
